Phase I Study of HSK46575 in Patients With Metastatic Castration-Resistant Prostate Cancer

This is a phase I, open-label, dose-escalation and expansion study to evaluate the safety, tolerability, PK（pharmacokinetics） and PD（pharmacodynamics） of HSK46575 when given orally in patients with metastatic castration-resistant prostate cancer.

Trial Details

NCT ID
NCT07007910
Phase
PHASE1
Sponsor
Haisco Pharmaceutical Group Co., Ltd.
Status
RECRUITING
Cancer Type
Prostate Cancer
Interventions
  • HSK46575
Locations (sample)
  • Chengdu, Sichuan, China|30.66667,104.06667

Key Eligibility Criteria

  • Male, aged ≥18 years;
  • ECOG (Eastern Cooperative Oncology Group) 0-1, expected survival of ≥ 3 months;
  • Histology or cytology confirmed adenocarcinoma of the prostate;
  • Radiological evidence of metastatic bone or soft tissue lesions;

For full eligibility, visit ClinicalTrials.gov.

Check If You May Be Eligible

Trialify translates complex eligibility criteria into plain yes-or-no questions to help you understand if this trial might be right for you.

Find Prostate Cancer Trials on Trialify →